BioCentury
ARTICLE | Company News

Affymax, Takeda deal

June 16, 2014 7:00 AM UTC

Takeda is terminating a 2006 deal with Affymax to co-develop and co-commercialize Omontys peginesatide, effective Sept. 10. The pharma also will withdraw an NDA in the U.S. for the once-monthly anemia drug. According to the companies, the pharma was unable to identify the root cause for postmarketing hypersensitivity reactions to Omontys, which led Affymax and Takeda to voluntarily recall all lots of the drug last year. Takeda withdrew an MAA in Europe for Omontys in July 2013 (see BioCentury, March 4, 2013 & July 15, 2013) ...